Nasdaq · CIK 0001655759
ARVN ARVINAS, INC.
Insider trading from SEC Form 4. Last filing Jun 30, 2025. Close $7.64 on Oct 9, 2026, +9% from the 52-week low and -45% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
ARVNOct 9, 2026 · close 7.64
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ARVINAS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Andrew Saik Chief Financial Officer sell | $43k 5,700 shares | -3% | +28% from low-72% from high | |
| 23Weak | Angela M Cacace Chief Scientific Officer sell | $19k 2,583 shares | -2% | +23% from low-73% from high | |
| 23Weak | Noah Berkowitz Chief Medical Officer sell | $74k 8,658 shares | -7% | +1% from low-70% from high | |
| 58Moderate | John G Houston President and CEO sell | $524k 31,338 shares | -3% | 0% from low-40% from high | |
| 46Moderate | Ian Taylor President, R&D sell | $151k 9,020 shares | -5% | 0% from low-40% from high | |
| 38Weak | Angela M Cacace Chief Scientific Officer sell | $70k 4,207 shares | -4% | 0% from low-40% from high | |
| 30Weak | David K Loomis Chief Accounting Officer sell | $20k 1,214 shares | -6% | 0% from low-40% from high | |
| 15Weak | David K Loomis Chief Accounting Officer sell | $10k 460 shares | -5% | - |
Transactions
The last 48 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2025 | Sunil Agarwal director | AGrant or award Common Stock | +16,025 | $0.00 | $0 | 30,166 | Jun 30, 2025 |
| Jun 25, 2025 | Sunil Agarwal director | AGrant or award Stock Option (right to buy)derivative | +23,105 | $0.00 | $0 | 23,105 | Jun 30, 2025 |
| Jun 25, 2025 | John D Young director | AGrant or award Common Stock | +16,025 | $0.00 | $0 | 26,045 | Jun 27, 2025 |
| Jun 25, 2025 | Alsup Laurie Smaldone director | AGrant or award Common Stock | +16,025 | $0.00 | $0 | 26,045 | Jun 27, 2025 |
| Jun 25, 2025 | Briggs Morrison director | AGrant or award Common Stock | +16,025 | $0.00 | $0 | 46,021 | Jun 27, 2025 |
| Jun 25, 2025 | Linda Bain director | AGrant or award Common Stock | +16,025 | $0.00 | $0 | 26,045 | Jun 27, 2025 |
| Jun 25, 2025 | Edward Moore Kennedy Jr. director | AGrant or award Common Stock | +16,025 | $0.00 | $0 | 39,430 | Jun 27, 2025 |
| Jun 25, 2025 | Everett Cunningham director | AGrant or award Common Stock | +16,025 | $0.00 | $0 | 26,045 | Jun 27, 2025 |
| Jun 25, 2025 | Leslie Norwalk V director | AGrant or award Common Stock | +16,025 | $0.00 | $0 | 26,045 | Jun 27, 2025 |
| Jun 25, 2025 | Everett Cunningham director | AGrant or award Stock Option (right to buy)derivative | +23,105 | $0.00 | $0 | 23,105 | Jun 27, 2025 |
| Jun 25, 2025 | Linda Bain director | AGrant or award Stock Option (right to buy)derivative | +23,105 | $0.00 | $0 | 23,105 | Jun 27, 2025 |
| Jun 25, 2025 | John D Young director | AGrant or award Stock Option (right to buy)derivative | +23,105 | $0.00 | $0 | 23,105 | Jun 27, 2025 |
| Jun 25, 2025 | Briggs Morrison director | AGrant or award Stock Option (right to buy)derivative | +23,105 | $0.00 | $0 | 23,105 | Jun 27, 2025 |
| Jun 25, 2025 | Leslie Norwalk V director | AGrant or award Stock Option (right to buy)derivative | +23,105 | $0.00 | $0 | 23,105 | Jun 27, 2025 |
| Jun 25, 2025 | Alsup Laurie Smaldone director | AGrant or award Stock Option (right to buy)derivative | +23,105 | $0.00 | $0 | 23,105 | Jun 27, 2025 |
| Jun 25, 2025 | Edward Moore Kennedy Jr. director | AGrant or award Stock Option (right to buy)derivative | +23,105 | $0.00 | $0 | 23,105 | Jun 27, 2025 |
| Jun 24, 2025 | Andrew Saik Chief Financial Officer | SOpen-market sale Common Stock | -5,700 | $7.61 | $43k | 164,401 | Jun 24, 2025 |
| Jun 17, 2025 | Angela M Cacace Chief Scientific Officer | SOpen-market sale Common Stock | -2,583 | $7.49 | $19k | 154,248 | Jun 18, 2025 |
| May 9, 2025 | David K Loomis Chief Accounting Officer | AGrant or award Common Stock | +11,825 | $0.00 | $0 | 30,688 | May 13, 2025 |
| May 9, 2025 | Andrew Saik Chief Financial Officer | AGrant or award Common Stock | +59,600 | $0.00 | $0 | 170,101 | May 13, 2025 |
| May 9, 2025 | Noah Berkowitz Chief Medical Officer | AGrant or award Common Stock | +59,600 | $0.00 | $0 | 169,623 | May 13, 2025 |
| May 9, 2025 | Angela M Cacace Chief Scientific Officer | AGrant or award Common Stock | +59,600 | $0.00 | $0 | 156,831 | May 13, 2025 |
| May 9, 2025 | Angela M Cacace Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +91,000 | $0.00 | $0 | 91,000 | May 13, 2025 |
| May 9, 2025 | Noah Berkowitz Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +91,000 | $0.00 | $0 | 91,000 | May 13, 2025 |
| May 9, 2025 | Andrew Saik Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +91,000 | $0.00 | $0 | 91,000 | May 13, 2025 |
| May 9, 2025 | David K Loomis Chief Accounting Officer | AGrant or award Stock Option (right to buy)derivative | +18,100 | $0.00 | $0 | 18,100 | May 13, 2025 |
| Mar 18, 2025 | Noah Berkowitz Chief Medical Officer | SOpen-market sale Common Stock | -8,658 | $8.59 | $74k | 110,023 | Mar 19, 2025 |
| Feb 24, 2025 | Ian Taylor President, R&D | SOpen-market sale Common Stock | -7,356 | $16.75 | $123k | 160,785 | Feb 25, 2025 |
| Feb 24, 2025 | David K Loomis Chief Accounting Officer | SOpen-market sale Common Stock | -1,214 | $16.75 | $20k | 18,863 | Feb 25, 2025 |
| Feb 24, 2025 | Angela M Cacace Chief Scientific Officer | SOpen-market sale Common Stock | -3,061 | $16.75 | $51k | 98,377 | Feb 25, 2025 |
| Feb 24, 2025 | John G Houston President and CEO | SOpen-market sale Common Stock | -26,184 | $16.75 | $439k | 1,162,634 | Feb 25, 2025 |
| Feb 24, 2025 | Ian Taylor President, R&D | SOpen-market sale Common Stock | -1,664 | $16.55 | $28k | 159,121 | Feb 25, 2025 |
| Feb 24, 2025 | Angela M Cacace Chief Scientific Officer | SOpen-market sale Common Stock | -1,146 | $16.55 | $19k | 97,231 | Feb 25, 2025 |
| Feb 24, 2025 | John G Houston President and CEO | SOpen-market sale Common Stock | -5,154 | $16.55 | $85k | 1,157,480 | Feb 25, 2025 |
| Feb 13, 2025 | John G Houston President and CEO | AGrant or award Common Stock | +152,000 | $0.00 | $0 | 1,188,681 | Feb 18, 2025 |
| Feb 13, 2025 | David K Loomis Chief Accounting Officer | AGrant or award Common Stock | +10,584 | $0.00 | $0 | 18,624 | Feb 18, 2025 |
| Feb 13, 2025 | Andrew Saik Chief Financial Officer | AGrant or award Common Stock | +49,092 | $0.00 | $0 | 110,501 | Feb 18, 2025 |
| Feb 13, 2025 | Ian Taylor Chief Scientific Officer | AGrant or award Common Stock | +20,619 | $0.00 | $0 | 168,141 | Feb 18, 2025 |
| Feb 13, 2025 | Noah Berkowitz Chief Medical Officer | AGrant or award Common Stock | +55,229 | $0.00 | $0 | 118,681 | Feb 18, 2025 |
| Feb 13, 2025 | Angela M Cacace Chief Scientific Officer | AGrant or award Common Stock | +49,092 | $0.00 | $0 | 100,944 | Feb 18, 2025 |
| Feb 13, 2025 | Noah Berkowitz Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +84,330 | $0.00 | $0 | 84,330 | Feb 18, 2025 |
| Feb 13, 2025 | Angela M Cacace Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +74,960 | $0.00 | $0 | 74,960 | Feb 18, 2025 |
| Feb 13, 2025 | Ian Taylor Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +31,483 | $0.00 | $0 | 31,483 | Feb 18, 2025 |
| Feb 13, 2025 | Andrew Saik Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +74,960 | $0.00 | $0 | 74,960 | Feb 18, 2025 |
| Feb 13, 2025 | John G Houston President and CEO | AGrant or award Stock Option (right to buy)derivative | +232,000 | $0.00 | $0 | 232,000 | Feb 18, 2025 |
| Feb 13, 2025 | David K Loomis Chief Accounting Officer | AGrant or award Stock Option (right to buy)derivative | +16,176 | $0.00 | $0 | 16,176 | Feb 18, 2025 |
| Nov 8, 2023 | David K Loomis Chief Accounting Officer | SOpen-market sale Common Stock | -229 | $17.05 | $3,904 | 8,271 | Nov 12, 2024 |
| Nov 7, 2024 | David K Loomis Chief Accounting Officer | SOpen-market sale Common Stock | -231 | $27.69 | $6,396 | 8,040 | Nov 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Sunil Agarwaldirector
- Linda Baindirector
- Noah BerkowitzChief Medical Officer
- Angela M CacaceChief Scientific Officer
- Everett Cunninghamofficer, director
- John G HoustonPresident and CEO
- Edward Moore Kennedy Jr.director
- David K LoomisChief Accounting Officer
- Briggs Morrisondirector
- Leslie Norwalk Vdirector
- Andrew SaikChief Financial Officer
- Alsup Laurie Smaldonedirector
- Ian TaylorPresident, R&D
- John D Youngdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.